Early tumor-cell gene expression changes may predict the response to first-line bortezomib-based therapy in patients with newly diagnosed multiple myeloma. — Konstantinos Liapis (2016) | RDL Network
Early tumor-cell gene expression changes may predict the response to first-line bortezomib-based therapy in patients with newly diagnosed multiple myeloma.
Article 2016 en
Authors
KL
Konstantinos Liapis
EK
Efstathios Kastritis
TB
Tina Bagratouni
Abstract
1 min read
Our results suggest that BIRC5 and KIAA1754 gene-expression changes may predict the response to bortezomib-based therapy. These data may have relevance for the stratification and early adaptation of first-line treatment in patients with newly diagnosed MM.
Monika Engelhardt, Evangelos Terpos, Martina Kleber, Francesca Gay, Ralph Wäsch, Gareth J. Morgan, Michèle Cavo, Niels W.C.J. van de Donk, Andreas Beilhack, Benedetto Bruno, Hans Erik Johnsen, Roman Hájek, Christoph Driessen, Heinz Ludwig, Meral Beksaç, Mario Boccadoro, Christian Straka, S. Brighen, Martin Gramatzki, Alessandra Larocca, H M Lokhorst, Valeria Magarotto, Fortunato Morabito, Meletios A Dimopoulos, Hermann Einsele, Pieter Sonneveld, Antonio Palumbo
Discussion(0)
No comments yet. Be the first to comment.